Review anchor
Chymotrypsin-like elastase family member 2A
SINGLE PROTEIN · Sus scrofa
As of 2026-09-13
Evidence Snapshot
Chymotrypsin-like elastase family member 2A
CHEMBL2407
SINGLE PROTEIN
Sus scrofa
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Chymotrypsin-like elastase family member 2A as ChEMBL target CHEMBL2407, mapped to UniProt P08419. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2407
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08419
Chymotrypsin-like elastase family member 2A
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Chymotrypsin-like elastase family member 2A matters
Chymotrypsin-like elastase family member 2A is reviewed as Chymotrypsin-like elastase family member 2A (UniProt P08419); the current evidence base includes 0 approved drugs, 333 compounds, and 98 assays, with lead potency reaching pChEMBL 9.4.
Protein context
Chymotrypsin-like elastase family member 2A
Chymotrypsin-like elastase family member 2A Sequence length is 269 aa.
Review this target as Chymotrypsin-like elastase family member 2A, mapped to UniProt P08419. Sequence length is 269 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P08419
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 333 compounds, and 98 assays for this target. The dominant activity type is IC50. CHEMBL290577 is the current potency anchor at pChEMBL 9.4.
Use CHEMBL290577 as the tractability anchor when discussing potency (pChEMBL 9.4).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 9.4
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Chymotrypsin-like elastase family member 2A matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08419, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
333
Total Compounds
98
Total Assays
0
Approved Drugs
IC50: 180.0, KI: 42.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL290577
|
9.4 | Ki | — |
|
|
No preferred name
CHEMBL108294
|
9.2 | IC50 | — |
|
|
No preferred name
CHEMBL288176
|
8.7 | Ki | — |
|
|
No preferred name
CHEMBL3349045
|
8.5 | Ki | — |
|
|
No preferred name
CHEMBL291026
|
8.3 | Ki | — |
Source Header